AP184A - An improved process for the preparation of substituted indolone derivatives. - Google Patents

An improved process for the preparation of substituted indolone derivatives. Download PDF

Info

Publication number
AP184A
AP184A APAP/P/1991/000251A AP9100251A AP184A AP 184 A AP184 A AP 184A AP 9100251 A AP9100251 A AP 9100251A AP 184 A AP184 A AP 184A
Authority
AP
ARIPO
Prior art keywords
preparation
compound
equiv
water
phenyl
Prior art date
Application number
APAP/P/1991/000251A
Other versions
AP9100251A0 (en
Inventor
Timothy Charles Walsgrove
Robert Gordon Giles
Original Assignee
Smithkline & French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline & French Laboratories Ltd filed Critical Smithkline & French Laboratories Ltd
Publication of AP9100251A0 publication Critical patent/AP9100251A0/en
Application granted granted Critical
Publication of AP184A publication Critical patent/AP184A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/39Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups
    • C07C205/40Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups and esterified hydroxy groups bound to acyclic carbon atoms of the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/12Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78Benzoic acid esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

A process for the preparation of a compound of structure (i)in which n is 1 to 3 and each group r is hydrogen or c1-4alkyl, which comprises, reaction of a compound of structure (ii)in which r1 is c1-4alkyl, phenyl or substituted phenyl and n is 1 to 3, with an anime hnr2 in which r is as described for structure (i), and optionally thereafter forming a salt.

Description

- 1 PROCESS
The present invention relates to an improved process for the preparation of substituted indolone derivatives.
Such compounds are in particular described in EP-0113964-B as being useful in cardiovascular therapy, and in EP-299602-A as agents useful in the treatment of Parkinson's disease.
Processes for the preparation of substituted indolone derivatives have been described in the art, for example in EP-113964-B, and in EP-300614-A1. In particular, EP-300614-A1 describes a series of steps which allow preparation of compounds of the structure
in which R is, inter alia, hydrogen or C1_4alkyl and n is l to 3, the final step of which comprises displacement by an amine of a halogen leaving group, from the precursor compounds of structure
(B) in which X is halogen.
22022
- 2 The present invention provides an improvement to the reaction sequence disclosed in EP-300614-Al and provides, in a first aspect, a process for the preparation of a compound of structure (I)
in which n is 1 to 3 and each group R is hydrogen or Cj^alkyl, which comprises, reaction of a compound of structure (II)
in which n is l to 3 and R1 is C1-4alkyl, phenyl or substituted phenyl with an amine of structure HNR2 where R is as described for structure (I), and optionally thereafter forming a salt.
Suitably, one of the groups R is hydrogen and the other is hydrogen or C1_4alkyl; preferably, both groups R are C1_4alkyl, in particular propyl. Suitably n is l to 3; preferably n is 2.
Suitably R1 is C1_4alkyl such as methyl, phenyl or substituted phenyl, for example p-methylphenyl; preferably R1 is p-methylphenyl.
22022
- 3 Suitably, the reaction is carried out in a variety of solvents at elevated temperature, preferably in water, at a temperature of between about 80 and about 90°C.
The compounds of structure (II) are novel and themselves form a further aspect of the invention.
Surprisingly, it has been found that the reaction described herein provides the desired product in much higher yields than previously obtained using the prior art process described in EP-300614-A in which a halogen leaving group is displaced by an amine.
More particularly, it has been found that, for example when used to prepare the compound 4-[2-(di-npropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride salt ((I), n=2, R=n-propyl), from the corresponding precursor (II) in which the leaving group is bromine (rather than OSO2R1), isolated yields of about
60% are obtained, whereas yields of up to 87% have been obtained from compounds of structure (II) in which an oxygen leaving group is present.
This significant increase in yield could not have been predicted from the prior art disclosure of EP-300614-A or from general prior art knowledge.
As referred to above, the method is particularly useful for the preparation of the compound 4-[2-(di-n30 propylamino)ethyl]-l,3-dihydro-2H-indol-2-one hydrochloride salt (INN:ropinirole), a compound useful for the treatment of Parkinson's disease (EP-299-602-A). In addition, when used to prepare the compounds of the invention (and in particular ropinirole) the processes used to prepare the compounds (II), proceed via important
AP 0 0 0 1 8 4
- 4 22022 intermediates which themselves fora a further aspect of the invention. In particular, the compounds (II) can be prepared via the following route :
(VI)
(V)
R = halogen, e.g. chlorine
(f) (II)
22022
- 5 (a) R2COC1, ZnCl2, CH2CI2 -10-0°; CgH12N4,
IMS, Δ; 50%aq. AcOH, Δ; Na2S2O5, IMS, H20, CH2C12, NaHCO-j, 5-12 °C;
(b) NaOMe, MeNO2, MeOH, 0°; MeOH/H2O, HC1;
(c) FeCl3, AcCl, CH2C12;
(d) NaH2PO2, 10% Pd/C, EtOAc/H2O;
(e) NaOH, MeOH/H2O, Δ;
(f) R1SO2Cl/Pyridine.
In the above-noted scheme, R1 and n are as described for formula (II) and R2 can be for example, Ci_4alkyl, in particular methyl, phenyl or substituted phenyl. Starting compounds (C), are known or can be prepared by standard methods. For example, when used to prepare the preferred compounds of structure (II) in which n is 2, the starting material (C) in which n is 2, i.e. isochroman, is commercially available.
In a further aspect of the invention there is therefore provided compounds of structure (III), (IV), (V), (VI) and (VII) as defined in the scheme above.
Compounds of structure (V) and (VI) can be represented by the following combined structure (VIA):
AP 0 0 0 1 8 4
22022
(VIA) in which n is l to 3, R2 is substituted phenyl, and R3'
C1_4alkyl, phenyl or is hydrogen or halogen.
Compounds of structure (III) and (IV) can be represented by the following combined structure (IVA):
(CH2)nOCR‘ (IVA) in which n and R2 are as described for structure (VIA) and R4 is CHO or CH=CHNO2.
The following examples serve to illustrate the invention. Temperatures are recorded in degrees centigrade.
22022
- 7 Example 1
Preparation of 4-r2-(di-n-propylamino)ethvl1-1,3-dihydro2H-indol-2-one hydrochloride 5
A. Preparation of 2-formyl phenethyl benzoate.
To a stirred suspension of ZnCl2 (61 g, 1.2 equiv.) in CH2Cl2 (250 ml) at 5* was added a solution of PhCOCl 10 (63 g, 1.2 equiv.) in CH2C12 (50 ml) followed by isochroman (50 g, 1 equiv.). [Max temperature during addition 8 12°]. The resulting mixture was stirred at 5° for one hour, by which time, all the isochroman had been consumed.
The reaction mixture was poured onto ice (300 g) and the organic layer was removed and washed with water (2 x 300 ml).
The organic layer was then added to hexamethylenetetramine (105 g, 2 equiv.) in 94% IMS (375 ml), and the reaction mixture was heated in order to remove CH2C12 via distillation (ca. 90 minutes). 50% Aqueous acetic acid (375 ml) was then added, and the reaction was further heated in order to remove the IMS present via distillation. The reaction mixture was then cooled, and extracted with CH2C12 (375 ml). The organic layer was washed with water (300 ml), 7% aqueous sodium bicarbonate solution (300 ml) and again with water (300 ml).
To the methylene chloride layer containing crude product was added sodium metabisulphite (77 g), IMS (65 ml) and water (110 ml). The reaction mixture was then heated in order to remove CH2C12 [maximum pot temperature β 50·, maximum distillate temperature @ 45°]
AP 0 0 0 1 8 4
22022
- 8 and then cooled to -10°, by which time a thick white precipitate was produced. CH2C12 (375 ml) was then added, and the white solid was collected at the pump, and washed with cold, fresh CH2C12 (75 ml).
The damp bisulphate addition complex was added, in portions, to a 7% aqueous sodium bicarbonate solution (1000 ml) at 20-25°. The pure aldehyde was then extracted into CH2C12 (375 ml), and the organic layer was then washed with water (2 x 300 ml). After drying (MgSO4) and filtration, the organic solution was concentrated in vacuo to a base temperature of 70° to leave a pale green mobile oil (61 g, 64%).
In respect of this reaction on a 20 kg scale on pilot-plant facilities, a 26.6 kg (70% yield) of 2-formyl phenethyl benzoate was obtained.
B. Preparation of 2-(2'-benzoyloxyethyl)-B-nitrostyrene.
To a stirred solution of 2-formylphenethyl benzoate (10 g, 1 equiv.) in methanol (40 ml) containing a small amount of 30% wt/wt sodium methoxide in methanol solution (0.5 g), at -10°, was added nitromethane (3.6 g, 1.5 equiv.) and sodium methoxide in methanol (30% wt/wt 8.85 g,
1.2 equiv. total) over a temperature range of -10-0°.
The reaction mixture was then stirred at 10° for 50 minutes, before being added over a 10 minute period to a rapidly stirred methanol/conc. hydrochloric acid (60/60 ml) solution over the temperature range -10-0°.
The quenched reaction mixture was stirred at 0° for 10 minutes before being warmed up to 30° and water (60 ml) was slowly added over a 30 minute period. The yellow solid which was formed was collected at the pump and
22022
- 9 washed with 50% aqueous methanol (50 ml) and dried at 40-50° overnight. Yields of the title compound in the region of 85-88% were obtained using this method which contains impurities in the 1-4% wt/wt range.
Recrystallisation from isopropanol (3 ml solvent/g product, recovery § 80%) gave the pure title compound.
C. Preparation of 4-(2'-benzoyloxyethyl)-3-chloro1,3-dihydro-2H-indol-2-one
To a stirred suspension of ferric chloride (54.6 g, equiv.) in CH2Cl2 (250 ml) at 5° was added acetyl chloride (13.2 g, 2 equiv.), followed by a solution of the product from (B) (25 g, 1 equiv.) in CH2C12 (125 ml) over the temperature range 5-10°. The cooling source was then removed and the reaction temperature rose to 27° over a 30 minute period and after a further 30 minutes, a reaction temperature of 23° was obtained.
The reaction mixture was cooled to 5° and water (375 ml) was added at such a rate that the temperature was kept below 15°. After the addition of water was complete, the quenched mixture was heated to 30° and the organic layer was isolated. The organic layer was then washed with water (3 x 300 ml) at a temperature of 30° for each wash. The organic layer was filtered and then concentrated down to a volume of 6 150 ml, by which time precipitation of the product had started to occur. Light petroleum (60/80) (100 ml) was then added to the hot
CH2C12 mixture and the resulting precipitate was cooled to 5° for 30 minutes. The product was collected at the pump and washed with CH2Cl2/petrol (60/80) (3:2.50 ml) and then dried. This gave the title compound
16.12 g, 61% yield in the form of an off-white solid.
22022
- 10 D. Preparation of 4-(2'-benzoyloxyethyl)-l,3-dihydro2H-indol-2-one
The product from C (46.7 g, 1 equiv.) and 10% Pd/C (60% wt/wt H2O, 0.011 equiv Pd) were stirred in ethyl acetate (600 ml) and heated to reflux. To this mixture was added an aqueous solution of sodium hypophosphite hydrate (40 g, 2.55 equiv.) in water (100 ml) over a period of 20 minutes. The reaction mixture was heated for a further 30 minutes, and the hot mixture was then filtered through celite and diluted with hot water (100 ml). The resulting water layer was removed and the ethyl acetate solution vas concentrated to a volume of 6 250 ml and cooled to 0*. The resulting precipitate was collected at the pump and dried at 60° overnight. This gave the title compound, 36 g, 86% in the form of a white solid.
E. Preparation of 4-(2'-hydroxyethyl)-l,3-dihydro-2Hindol-2-one.
The product from 0 (10.25 g, 1 equiv.) and solid sodium hydroxide (1.56 g) were stirred in water (50 ml) and methanol (20 ml) and heated to reflux for 2 hours. Methanol was then removed via distillation and the reaction mixture was then cooled. The pH of the reaction mixture was adjusted to 7 and the creamy white precipitate was collected at the pump, washed with water (120 ml) and dried at 80° overnight to give the title compound, 5.56 g, 89%.
22022
- 11 F. Preparation of 2-(2'-oxo-2,3-dihydro-4-indolyl)ethyl toluene sulphonate.
To a stirred solution of the product from E (20 g,
1 equiv.) in pyridine (90 ml, 10 equiv.) at 5-10° was added a solution of p-toluene sulphonyl chloride (30.2 g,
1.4 equiv.) in CH2C12 (90 ml) at such a rate as to keep the reaction temperature below 10°. The mixture was then stirred at 5-10° for 2 hours before being added to a stirred solution comprising of concentrated hydrochloric acid (110 ml), water (100 ml) and CH2Cl2 (90 ml) at a temperature below 15®. The organic layer was removed, and the aqueous phase was extracted with CH2C12 (50 ml). The combined organic extracts were washed with water (2 x 100 ml) and then filtered. CH2C12 (150 ml) was removed via distillation and the residual solution was diluted with 94% IMS (100 ml). Distillation was continued in order to completely remove CH2C12. Water (50 ml) was then added, and the solution was then cooled to 0®. The product was collected at the pump and washed with cold 33% aqueous IMS (60 ml) to give the title compound, 34 g, 91% yield as an off-white solid.
G. Preparation of 4-(2-(di-n-propylamino)ethyl]-l,325 dihydro-2H-indol-2-one hydrochloride
Water (420 ml) and di-n-propylamine (124 ml) were mixed and thoroughly purged with N2 at 40®C for 10 minutes. The product from F (30 g) was then added and the mixture was heated to 80-5®, under an N2 atmosphere for 2 hours. After this time, the two-phase mixture was allowed to separate and the water layer was removed and replaced with fresh water (210 ml) which had been purged with nitrogen for 10 minutes at ambient temperature.
Excess di-n-propylamine was removed via vacuum azeotropic
AP 0 0 0 1 8 4
22022
- 12 distillation, before the mixture was cooled, and acidified using cone, hydrochloric acid (22 ml). The acidic aqueous phase was extracted twice with CH2C12 (100 ml and ml) and these extracts were discarded.
The aqueous phase was then basified to pH 12-14 using 50% aqueous sodium hydroxide solution, before being extracted with CH2C12 (100 ml and 50 ml). The organic layer was washed twice with water (2 x 100 ml) and then diluted with isopropanol (240 ml) , and acidified using cone, hydrochloric acid (17.5 ml). CH2C12 was then removed via atmospheric distillation to a maximum vapour temperature of 75*C. On cooling, an off-white precipitate was formed and this was cooled to 0· before the solid was collected at the pump, and washed with cold isopropanol. After drying, the title compound (23.3 g) was isolated in a 87% yield as an off-white solid.
Example 2: Preparation of 4-Γ2-(di-n-propvlamino)ethyll1.3-dihvdro-2H-indol-2-one hydrochloride from
2-(2/-oxo-2.3-dihvdro-4-indolvl)ethvl methanesu lphonate (A) Preparation of 2-(2'-oxo-2,3-dihvdro-4-indolvl)ethyl methanesulphonate
To a suspension of the product from 1(E) (10 g, equiv.) in pyridine (60 ml) at 0°C, was added, in small portions, methanesulphonyl chloride (7.1 g, 1.1 equiv.) making sure the temperature did not rise above 5°C. The mixture was then stirred at 0°C for one hour. T.l.c. analysis showed that the reaction had gone to completion.
The reaction mixture was quenched into 2.4M hydrochloric acid (250 ml) at 0-10°C, and was then
22022
- 13 extracted with ethyl acetate (2 x 200 ml). The combined extracts were then washed with water (2 x 100 ml), dried, filtered, and concentrated in vacuo to give the title compound as a white solid. This was recrystallised from
94% IMS to give an isolated yield of 9.5 g, 66%.
(B) Preparation of 4-(2-(di-n-propvlamino)ethvn-l, 3dihvdro-2H-indol-2-one hydrochloride
The methanesulphonate derivative from (A) (8.3 g, equiv.) was stirred with di-n-propylamine (32.4 g, equiv.) and water (120 ml) at 80’C for two hours.
HPLC analysis showed that the reaction had gone to completion.
Excess di-n-propylamine was removed by vacuum azeotropic distillation. The mixture was then cooled, and basified to pH 14 using solid sodium hydroxide. The basic aqueous mixture was then extracted with dichloromethane (3 x 50 ml), and the combined extracts were washed with water (2 x 100 ml). After drying and filtration, the organic solution was concentrated totally in vacuo to leave a purple oil.
The oil was dissolved in isopropanol (200 ml) and cooled to 0°C, before cone, hydrochloric acid was added. The resulting precipitate was collected by filtration, washed with cold isopropanol (10 ml) and dried to give the title compound, 7.1 g, 75%.
Example 3: Preparation of 4-r2-(di-n-propylamino)ethvl11,3-dihvdro-2H-indol-2-one hydrochloride from
2-(2z-oxo-2,3-dihvdro-4-indolvl)ethyl benzenesulphonate
AP 0 0 0 1 8 4
22022
- 14 (A) Preparation of 2-(2ζ-οχο-2.3-dihvdro-4-indolvl)ethyl benzenesulphonate
To a suspension of the product from 1(E) (5 g, equiv.) in pyridine (30 ml) at -30°C, was added benzenesulphonyl chloride (5.5 g, 1.1 equiv.), ensuring the temperature remained below -20°C. The mixture was then stirred at -30°C for 5 hours.
The reaction mixture was quenched into 2.4M hydrochloric acid (125 ml) at -10 to -5°C, and the acidic aqueous phase was then extracted into ethyl acetate (200 and 100 ml). The combined organic extracts were washed with water (150 ml), dried, filtered and then concentrated in vacuo to give a beige solid. This was recrystallised from IMS giving the title compound, 6.1 g, 69%.
(B) Preparation of 4-r2-(di-n-propvlamino)ethvll-1.3dihvdro-2H-indol-2-one hydrochloride
The benzenesulphonyl derivative from (A) (5 g, equiv.) was stirred with di-n-propylamine (16 g, equiv.) and water (100 ml) at 80°C for 2¼ hours.
Excess di-n-propylamine was removed via vacuum azeotropic distillation. The remaining aqueous phase was then basified to pH 14 using solid sodium hydroxide, and then extracted using dichloromethane (2 x 50 ml) . The combined extracts were washed with water (2 x 100 ml) , dried, and concentrated in vacuo to leave a purple oil.
The oil was dissolved in isopropanol (100 ml) and the solution cooled to 0eC, before cone, hydrochloric acid was added (5 ml) . Isopropanol (40 ml) was then removed via atmospheric distillation, before the mixture was cooled to 0°C to give a fine precipitate.
22022
- 15 The desired product was collected via filtration, washed with cold ispropanol (10 ml), and dried to give the desired product (3.3 g, 70%).
AP 0 0 0 1 8 4
22022

Claims (9)

  1. Claims
    1. A process for the preparation of a compound of structure (I) in which n is 1 to 3 and each group R is hydrogen or C1-4alkyl, which comprises, reaction of a compound of structure (II) (II) in which R1 is C1_4alkyl, phenyl or substituted phenyl and n is 1 to 3, with an amine HNR2 in which R is as described for structure (I), and optionally thereafter forming a salt.
  2. 2. A process according to claim 1 in which R1 is p-methyIpheny1.
  3. 3. A process according to claim 2 in which both groups R are C1_4alkyl and n is 2.
    22022
    - 17 4. A process according to claim l in which the compound of structure (I) prepared is:
  4. 4-[2-(di-n-propylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride (INN: ropinirole).
  5. 5. A process according to claim 2 in which the compound of structure (I) prepared is:
    4-[2-(di-n-propylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride (INN: ropinirole).
  6. 6. A compound of structure (II):
    in which n is 1 to 3 and R1 is C1_4alkyl, phenyl or 20 substituted phenyl.
  7. 7. A compound of structure (VII):
    AP 0 0 0 1
  8. 8 4 in which n is 1 to 3.
    I
    22022
    - 18 8. A compound of structure (VIA):
    (VIA) in which n is 1 to 3, R2 is C^alkyl, phenyl or substituted phenyl and R3' is hydrogen or halogen.
  9. 9. A compound of structure (IVA):
    Η ;
    2>n0CR (IVA) in which n is 1 to 3, R2 is C1_4alkyl, phenyl or substituted phenyl and R4 is CHO or CH=CHN02.
    /(?
    c C
APAP/P/1991/000251A 1990-04-17 1991-04-16 An improved process for the preparation of substituted indolone derivatives. AP184A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909008605A GB9008605D0 (en) 1990-04-17 1990-04-17 Process

Publications (2)

Publication Number Publication Date
AP9100251A0 AP9100251A0 (en) 1991-04-30
AP184A true AP184A (en) 1992-06-30

Family

ID=10674534

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1991/000251A AP184A (en) 1990-04-17 1991-04-16 An improved process for the preparation of substituted indolone derivatives.

Country Status (29)

Country Link
US (1) US5336781A (en)
EP (1) EP0526529B1 (en)
JP (2) JP2788548B2 (en)
KR (1) KR0180215B1 (en)
CN (1) CN1027892C (en)
AP (1) AP184A (en)
AT (1) ATE144251T1 (en)
AU (2) AU640006B2 (en)
CA (1) CA2080221C (en)
CY (1) CY1981A (en)
DE (1) DE69122753T2 (en)
DK (1) DK0526529T3 (en)
ES (1) ES2094812T3 (en)
FI (1) FI101148B (en)
GB (1) GB9008605D0 (en)
GR (1) GR3022261T3 (en)
HK (1) HK3097A (en)
HU (1) HU214822B (en)
IE (1) IE911262A1 (en)
IL (7) IL111028A (en)
MA (1) MA22133A1 (en)
MY (1) MY109628A (en)
NO (2) NO178396C (en)
NZ (1) NZ237819A (en)
PL (1) PL166736B1 (en)
PT (1) PT97375B (en)
SA (1) SA91110352B1 (en)
WO (1) WO1991016306A1 (en)
ZA (1) ZA912782B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
ES2137932T3 (en) * 1990-09-28 2000-01-01 Smithkline Beecham Corp PROCEDURE FOR THE PREPARATION OF WATER-SOLUBLE CAMPTOTECHE ANALOGS, AS WELL AS THE 10-HYDROXY-11-ALCOXI-6-CAMPTOTINE COMPOUNDS.
GB9300309D0 (en) * 1993-01-08 1993-03-03 Smithkline Beecham Plc Process
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
AR030557A1 (en) 2000-04-14 2003-08-27 Jagotec Ag A TABLET IN MULTI-MAP OF CONTROLLED RELEASE AND TREATMENT METHOD
WO2005074387A2 (en) * 2003-12-30 2005-08-18 Sun Pharmaceutical Industries Limited Novel crystal forms of 4-[2-di-n-propylamino)ethyl]-2 (3h)- indolone hydrochloride
US7378439B2 (en) * 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
WO2005105741A1 (en) * 2004-02-11 2005-11-10 Sun Pharmaceutical Industries Limited Substantially pure 4-[2-(di-n-propylamino)ethyl]-2(3h)-indolone hydrochloride
WO2005080333A1 (en) * 2004-02-19 2005-09-01 Torrent Pharmaceuticals Ltd Process for purification of ropinirole
US20070254941A1 (en) * 2006-04-21 2007-11-01 Glenmark Pharmaceuticals Limited Subtantially pure ropinirole hydrochloride, polymorphic form of ropinirole and process for their preparation
CN103130704B (en) * 2013-03-11 2019-03-22 上海奥博生物医药技术有限公司 It is a kind of to prepare 4- (2- ethoxy) -1,3- dihydro -2H- indol-2-one new method
CN103145604A (en) * 2013-03-19 2013-06-12 上海奥博生物医药技术有限公司 Method for preparing ropinirole key intermediate
CN105418482A (en) * 2015-11-23 2016-03-23 东南大学 Improved preparation method for ropinirole hydrochloride
CN108440376B (en) * 2018-05-08 2020-06-05 中国科学院成都生物研究所 Preparation method of ropinirole hydrochloride

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113964B1 (en) * 1982-12-07 1986-10-22 Smithkline Beckman Corporation 4-aminoalkyl-2(3h)-indolones
EP0299602A2 (en) * 1987-05-21 1989-01-18 Smith Kline & French Laboratories Limited Use of indolone derivatives for the preparation of medicaments for the treatment of Parkinsons disease
EP0300614A1 (en) * 1987-06-19 1989-01-25 Smith Kline & French Laboratories Limited Process for the preparation of substituted indolinone derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1154976A (en) * 1967-02-21 1969-06-11 Pfizer Ltd N-Phenyl Indoline Derivatives
JPS53101333A (en) * 1977-02-14 1978-09-04 Sagami Chem Res Center 3-acyloxymethyl-3,4:5,6-diepoxycyclohexane-1,2-diol and
IT1171624B (en) * 1980-11-12 1987-06-10 Thomae Gmbh Dr K INDOLINONES EQUIPPED WITH PHARMACEUTICAL PROPERTIES AND PROCEDURE FOR THEIR PRODUCTION
US4588790A (en) * 1982-03-24 1986-05-13 Union Carbide Corporation Method for fluidized bed polymerization
US4593033A (en) * 1985-04-24 1986-06-03 Merck & Co., Inc. Substituted indeno[2,1-c] pyridines useful as calcium channel blockers
FR2635104B1 (en) * 1988-08-03 1992-04-30 Synthelabo INDOLONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113964B1 (en) * 1982-12-07 1986-10-22 Smithkline Beckman Corporation 4-aminoalkyl-2(3h)-indolones
EP0299602A2 (en) * 1987-05-21 1989-01-18 Smith Kline & French Laboratories Limited Use of indolone derivatives for the preparation of medicaments for the treatment of Parkinsons disease
EP0300614A1 (en) * 1987-06-19 1989-01-25 Smith Kline & French Laboratories Limited Process for the preparation of substituted indolinone derivatives

Also Published As

Publication number Publication date
NO178396B (en) 1995-12-11
AP9100251A0 (en) 1991-04-30
JP3044013B2 (en) 2000-05-22
IL97867A0 (en) 1992-06-21
NZ237819A (en) 1993-05-26
IE911262A1 (en) 1991-10-23
GR3022261T3 (en) 1997-04-30
AU7656291A (en) 1991-11-11
EP0526529B1 (en) 1996-10-16
IL111030A0 (en) 1994-11-28
CA2080221C (en) 2000-11-14
JP2788548B2 (en) 1998-08-20
NO178396C (en) 1996-03-20
JPH05506029A (en) 1993-09-02
PT97375B (en) 1998-08-31
AU640006B2 (en) 1993-08-12
SA91110352B1 (en) 2001-11-12
CY1981A (en) 1997-09-05
KR0180215B1 (en) 1999-03-20
IL111028A0 (en) 1994-11-28
PT97375A (en) 1992-01-31
CN1056686A (en) 1991-12-04
WO1991016306A1 (en) 1991-10-31
HU9203261D0 (en) 1992-12-28
HK3097A (en) 1997-01-10
US5336781A (en) 1994-08-09
JPH10251205A (en) 1998-09-22
PL166736B1 (en) 1995-06-30
FI101148B (en) 1998-04-30
NO924028D0 (en) 1992-10-16
AU646771B2 (en) 1994-03-03
NO924028L (en) 1992-10-16
ZA912782B (en) 1992-11-25
FI924674A0 (en) 1992-10-15
HUT64742A (en) 1994-02-28
IL111028A (en) 1995-11-27
NO1999012I1 (en) 1999-06-18
IL111029A0 (en) 1994-11-28
DE69122753D1 (en) 1996-11-21
AU3566993A (en) 1993-06-03
IL111030A (en) 1995-11-27
IL97867A (en) 1995-11-27
DK0526529T3 (en) 1996-11-18
ATE144251T1 (en) 1996-11-15
CA2080221A1 (en) 1991-10-18
MA22133A1 (en) 1991-12-31
FI924674A (en) 1992-10-15
EP0526529A1 (en) 1993-02-10
DE69122753T2 (en) 1997-05-07
HU214822B (en) 1998-06-29
CN1027892C (en) 1995-03-15
ES2094812T3 (en) 1997-02-01
GB9008605D0 (en) 1990-06-13
IL111029A (en) 1995-11-27
MY109628A (en) 1997-03-31

Similar Documents

Publication Publication Date Title
AP184A (en) An improved process for the preparation of substituted indolone derivatives.
KR101461291B1 (en) Process for the manufacture of pharmaceutically active compounds
JP4018182B2 (en) Process for producing dihaloazolopyrimidines
CZ283215B6 (en) Process for preparing 3-(alpha-methoxy)methylenebenezofuranones
JP2846042B2 (en) Method for producing indolecarboxylic acid derivative
JP2682705B2 (en) A method for producing a 2,6-dichlorophenylaminobenzeneacetic acid derivative and a diphenylamine derivative.
US3933818A (en) Heterocyclic compounds
JP2622135B2 (en) Indene derivative and method for producing the same
Hayler et al. Some synthetic approaches to ropinirole (sk&f 101468‐a): A potent dopamine receptor agonist
JP2002530282A (en) Process for producing improved 7-azaindolyl-3-carboxylic acid
JPH08503980A (en) Polycyclic dye
NZ242374A (en) Phenyl alkyl ester compounds useful as intermediates in the preparation of 4-(aminoalkyl)-1,3-dihydro-2h-indol-2-one derivatives
KR100745449B1 (en) Method for production of benzofuranone oximes
JP2713874B2 (en) Intermediate used for producing 6-hydroxy-3-pyridinecarboxylic acid ester and method for producing the same
US5153330A (en) Thiapentanamide derivatives
SU528871A3 (en) The method of obtaining derivatives of 2- (1H) -quinazolinone
JPH02149546A (en) Preparation of naphthalene derivative
Dagger et al. JD Hayler, SLB Howie, RG Giles*, A. Negus, PW Oxley, TC Walsgrove*, and SE Walsh
JPH1053587A (en) Production of dioxotetrahydroindolizine derivative
JPH10501542A (en) Method for producing benzothiophene derivative
HU218210B (en) Process for producing substituted indol derivatives
SK281056B6 (en) Process for the preparation of 3-(alpha-methoxy)methylenebenzofuranones and intermediates therefor
JP2000514800A (en) 4- (4-oxocyclohexyl) benzamide